Reimagining Health and Disease

More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes?

A Flagship Pioneering company, Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order.

 

By manipulating this system with our unique Gene Traffic ControlTM Platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease.

 

With the Gene Traffic ControlTM Platform, Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.

a pioneering culture

Foghorn’s focus is on discovering, developing, and delivering revolutionary medicines to our fellow human beings.

We’re building a company that puts people first, never stops trying to battle disease, puts teamwork at the core of everything, and is driven by science to find new ways to think about solving disease.

meet the minds behind Gene Traffic ControlTM Platform

Foghorn envisions a world where we will cure diseases from within. Learn more below about the people working to make this vision a reality.

Charles Sawyers, MD – Scientific Advisory Board, Foghorn Therapeutics

Charles Sawyers, MD

Investigator, Howard Hughes Medical InstituteMarie-Josée and Henry Kravis Chair in Human Oncology and Pathogenesis and Chairman, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center

SAB CHAIR

Gerald Crabtree, MD, Founder of Foghorn Therapeutics

Gerald Crabtree, MD

Founder, Foghorn TherapeuticsDavid Korn Professor, Stanford University Medical SchoolInvestigator, Howard Hughes Medical Institute

Tony Kouzarides – Scientific Advisory Board member, Foghorn Therapeutics

Tony Kouzarides, PhD, FMedSci, FRS

Professor of Cancer Biology at the University of CambridgeDirector of the Milner Therapeutics Institute and Deputy Director of the Gurdon Institute

David Schenkein, MD

David Schenkein, MD

General Partner, Co-leader of Google Ventures life science team

Jeff Settleman, PhD

Jeff Settleman, PhD

Head of Oncology Research, Calico Life Sciences

Logo for Flagship Pioneering

A unique life science innovation enterprise, Flagship Pioneering conceives, creates, resources and develops first-in-category life sciences companies. Since its launch in 2000, the firm has applied a proprietary, hypothesis-driven innovation process to originate and foster nearly 100 scientific ventures, resulting in over $20 billion in aggregate value, 500+ issued patents and more than 40 clinical trials for novel therapeutic agents.